Table 1.
Demographics, clinical, and treatment characteristics of both groups.
| Characteristics | Combined (n = 21) | FMT (n = 13) | FMT-L (n = 8) | Univariate p value | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age mean (range) | 58.9 (17–91) | 56.8 (17–91) | 62.4 (53–77) | 0.764 | |
| Female gender n (%) | 12 (57.1) | 8 (61.5) | 4 (50) | 0.673 | |
|
| |||||
| Clinical data | |||||
| Current recurrence episode, n (%) | First | 16 (76.2) | 12 (92.3) | 4 (50) | 0.045 |
| Second | 3 (14.2) | 0 (0.0) | 3 (37.5) | 0.133 | |
| Third | 2 (9.5) | 1 (7.7) | 1 (12.5) | 0.421 | |
|
| |||||
| Previous antibiotic use | 21 (100) | 13 (100) | 8 (100) | NA | |
| Third-generation cephalosporin | 11 (52.3) | 6 (46.1) | 5 (62.5) | 0.659 | |
| Fluoroquinolone | 7 (33.3) | 5 (38.4) | 3 (37.5) | 0.841 | |
| Clindamycin | 5 (23.8) | 4 (30.7) | 2 (25.0) | 0.776 | |
| Other | 5 (23.8) | 5 (38.4) | 4 (50.0) | 0.94 | |
|
| |||||
| Bowel movements per day, mean (range) | Basal | 8.6 (3–20) | 8.9 (3–20) | 8.4 (3–12) | 0.779 |
| Day 2 | 3.2 (0–9) | 3.3 (0–9) | 3.25 (2–5) | 0.947 | |
| Day 90 | 1.4 (0–3) | 1.4 (0–3) | 1.5 (0–3) | 0.843 | |
|
| |||||
| Bristol score, mean (range) | Basal | 6.5 (5–7) | 6.46 (5–7) | 6.37 (5–7) | 0.803 |
| Day 2 | 5.4 (1–7) | 5.2 (1–7) | 5.87 (4–7) | 0.342 | |
| Day 90 | 3.6 (0–5) | 3.0 (1–4) | 4.75 (4–5) | 0.073 | |
|
| |||||
| Total body weight, mean (range) | Basal | 63 (38–94) | 60.7 (38–94) | 71.5 (49–89) | 0.216 |
| Day 90 | 66 (39–94) | 63.3 (39–94) | 74.3 (50–93) | 0.241 | |
|
| |||||
| Recurrence after FMT | 1 (4.8%) | 1 (7.7) | 0 (0.0) | 0.421 | |
| Minor adverse events, n (%) | Burping | 3 (14.2) | 2 (15.4) | 1 (12.5) | 0.854 |
| Constipation | 4 (19) | 4 (30) | 0 (0.0) | 0.241 | |
| Vomiting | 2 (9) | 1 (7.7) | 1 (12.5) | 0.075 | |
|
| |||||
| Severe adverse events, n (%) | 0 (0) | 0 (0.0) | 0 (0.0) | NA | |
The bold value indicates that it is statistically significant because it is lower than 0.05.